Skip Navigation


Brain Advance Access originally published online on June 4, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
126/7/1590    most recent
awg167v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gveric, D.
Right arrow Articles by Cuzner, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gveric, D.
Right arrow Articles by Cuzner, M. L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 126, No. 7, 1590-1598, July 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg167

Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors

Djordje Gveric1, Blanca Herrera1, Axel Petzold1, Daniel A. Lawrence2 and M. Louise Cuzner1

1 Department of Neuroinflammation, Institute of Neurology, University College London, London, UK, and 2 Department of Vascular Biology, American Red Cross Holland Laboratory, Rockville, Maryland, USA

Correspondence to: Dr Djordje Gveric, Department of Neuroinflammation, Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, UK E-mail: d.gueric{at}ion.ucl.ac.uk

Tissue plasminogen activator (tPA), a neuronal as well as the key fibrinolytic enzyme, is found concentrated on demyelinated axons in multiple sclerosis lesions together with fibrin(ogen) deposits. The decreased tPA activity in normal-appearing white and grey matter and lesions of multiple sclerosis is reflected in diminished fibrinolysis as measured by a clot lysis assay. Nonetheless, peptide products of fibrin, including D-dimer, accumulate on demyelinated axons—the result of fibrinogen entry through a compromised blood-brain barrier (BBB). Analysis of tissue samples on reducing and non-reducing polyacrylamide gels demonstrates complexes of tPA with plasminogen activator inhibitor-1 (PAI-1) but not with neuroserpin, a tPA-specific inhibitor concentrated in grey matter. As total tPA protein remains unchanged in acute lesions and the concentration of PAI-1 rises several fold, complex formation is a probable cause of the impaired fibrinolysis. Although the tPA-plasmin cascade promotes neurodegeneration in excitotoxin-induced neuronal death, in inflammatory conditions with BBB disruption it has been demonstrated to have a protective role in removing fibrin, which exacerbates axonal injury. The impaired fibrinolytic capacity resulting from increased PAI-1 synthesis and complex formation with tPA, which is detectable prior to lesion formation, therefore has the potential to contribute to axonal damage in multiple sclerosis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Mult SclerHome page
L. Lovrecic, S. Ristic, N. Starcevic-Cizmarevic, B. Brajenovic-Milic, Sasa Sega Jazbec, J. Sepcic, M. Kapovic, and B. Peterlin
PAI and TPA gene polymorphisms in multiple sclerosis
Multiple Sclerosis, March 1, 2008; 14(2): 243 - 247.
[Abstract] [PDF]


Home page
BrainHome page
C. Marik, P. A. Felts, J. Bauer, H. Lassmann, and K. J. Smith
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?
Brain, November 1, 2007; 130(11): 2800 - 2815.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
E. E. Benarroch
Tissue plasminogen activator: Beyond thrombolysis
Neurology, August 21, 2007; 69(8): 799 - 802.
[Full Text] [PDF]


Home page
Mult SclerHome page
V. Lehmensiek, S. Sussmuth, G. Tauscher, J. Brettschneider, S. Felk, F. Gillardon, and H. Tumani
Cerebrospinal fluid proteome profile in multiple sclerosis
Multiple Sclerosis, August 1, 2007; 13(7): 840 - 849.
[Abstract] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
I. B. Kovacs and J. Yamamoto
Spontaneous thrombolysis: a forgotten determinant of life or death.
Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 358 - 363.
[Abstract] [PDF]


Home page
Am. J. Pathol.Home page
E. East, D. Baker, G. Pryce, H. R. Lijnen, M. L. Cuzner, and D. Gveric
A Role for the Plasminogen Activator System in Inflammation and Neurodegeneration in the Central Nervous System during Experimental Allergic Encephalomyelitis
Am. J. Pathol., August 1, 2005; 167(2): 545 - 554.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D. Gveric, B. M. Herrera, and M. L. Cuzner
tPA Receptors and the Fibrinolytic Response in Multiple Sclerosis Lesions
Am. J. Pathol., April 1, 2005; 166(4): 1143 - 1151.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
A Petzold, M J Eikelenboom, G Keir, D Grant, R H C Lazeron, C H Polman, B M J Uitdehaag, E J Thompson, and G Giovannoni
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study
J. Neurol. Neurosurg. Psychiatry, February 1, 2005; 76(2): 206 - 211.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
M. Yepes and D. A. Lawrence
New Functions for an Old Enzyme: Nonhemostatic Roles for Tissue-Type Plasminogen Activator in the Central Nervous System
Experimental Biology and Medicine, December 1, 2004; 229(11): 1097 - 1104.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.